Global Basal insulin/GLP-1RA Combination Preparations Market Growth 2024-2030

Publication ID:

LPI08249867

Publication Date:

August 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Basal insulin/GLP-1RA combination preparations refer to fixed-dose combinations of basal insulin and GLP-1 receptor agonists(GLP-1RA)in a single formulation.These combinations are designed to provide comprehensive glycemic control for patients with type 2 diabetes mellitus by targeting both fasting and postprandial glucose levels.These combinations typically require fewer injections than using separate therapies and may reduce the risk of hypoglycemia compared to intensive insulin regimens alone.
The global Basal insulin/GLP-1RA Combination Preparations market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淏asal insulin/GLP-1RA Combination Preparations Industry Forecast鈥� looks at past sales and reviews total world Basal insulin/GLP-1RA Combination Preparations sales in 2023, providing a comprehensive analysis by region and market sector of projected Basal insulin/GLP-1RA Combination Preparations sales for 2024 through 2030. With Basal insulin/GLP-1RA Combination Preparations sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Basal insulin/GLP-1RA Combination Preparations industry.
This Insight Report provides a comprehensive analysis of the global Basal insulin/GLP-1RA Combination Preparations landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Basal insulin/GLP-1RA Combination Preparations portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Basal insulin/GLP-1RA Combination Preparations market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Basal insulin/GLP-1RA Combination Preparations and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Basal insulin/GLP-1RA Combination Preparations.
United States market for Basal insulin/GLP-1RA Combination Preparations is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Basal insulin/GLP-1RA Combination Preparations is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Basal insulin/GLP-1RA Combination Preparations is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Basal insulin/GLP-1RA Combination Preparations players cover Novo Nordisk, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Basal insulin/GLP-1RA Combination Preparations market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Insulin Degludec/Liraglutide
Insulin Glargine/Lixisenatide
Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Sanofi
Key Questions Addressed in this Report
What is the 10-year outlook for the global Basal insulin/GLP-1RA Combination Preparations market?
What factors are driving Basal insulin/GLP-1RA Combination Preparations market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Basal insulin/GLP-1RA Combination Preparations market opportunities vary by end market size?
How does Basal insulin/GLP-1RA Combination Preparations break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Basal insulin/GLP-1RA Combination Preparations Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Basal insulin/GLP-1RA Combination Preparations by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Basal insulin/GLP-1RA Combination Preparations by Country/Region, 2019, 2023 & 2030
2.2 Basal insulin/GLP-1RA Combination Preparations Segment by Type
2.2.1 Insulin Degludec/Liraglutide
2.2.2 Insulin Glargine/Lixisenatide
2.3 Basal insulin/GLP-1RA Combination Preparations Sales by Type
2.3.1 Global Basal insulin/GLP-1RA Combination Preparations Sales Market Share by Type (2019-2024)
2.3.2 Global Basal insulin/GLP-1RA Combination Preparations Revenue and Market Share by Type (2019-2024)
2.3.3 Global Basal insulin/GLP-1RA Combination Preparations Sale Price by Type (2019-2024)
2.4 Basal insulin/GLP-1RA Combination Preparations Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Basal insulin/GLP-1RA Combination Preparations Sales by Application
2.5.1 Global Basal insulin/GLP-1RA Combination Preparations Sale Market Share by Application (2019-2024)
2.5.2 Global Basal insulin/GLP-1RA Combination Preparations Revenue and Market Share by Application (2019-2024)
2.5.3 Global Basal insulin/GLP-1RA Combination Preparations Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Basal insulin/GLP-1RA Combination Preparations Breakdown Data by Company
3.1.1 Global Basal insulin/GLP-1RA Combination Preparations Annual Sales by Company (2019-2024)
3.1.2 Global Basal insulin/GLP-1RA Combination Preparations Sales Market Share by Company (2019-2024)
3.2 Global Basal insulin/GLP-1RA Combination Preparations Annual Revenue by Company (2019-2024)
3.2.1 Global Basal insulin/GLP-1RA Combination Preparations Revenue by Company (2019-2024)
3.2.2 Global Basal insulin/GLP-1RA Combination Preparations Revenue Market Share by Company (2019-2024)
3.3 Global Basal insulin/GLP-1RA Combination Preparations Sale Price by Company
3.4 Key Manufacturers Basal insulin/GLP-1RA Combination Preparations Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Basal insulin/GLP-1RA Combination Preparations Product Location Distribution
3.4.2 Players Basal insulin/GLP-1RA Combination Preparations Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Basal insulin/GLP-1RA Combination Preparations by Geographic Region
4.1 World Historic Basal insulin/GLP-1RA Combination Preparations Market Size by Geographic Region (2019-2024)
4.1.1 Global Basal insulin/GLP-1RA Combination Preparations Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Basal insulin/GLP-1RA Combination Preparations Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Basal insulin/GLP-1RA Combination Preparations Market Size by Country/Region (2019-2024)
4.2.1 Global Basal insulin/GLP-1RA Combination Preparations Annual Sales by Country/Region (2019-2024)
4.2.2 Global Basal insulin/GLP-1RA Combination Preparations Annual Revenue by Country/Region (2019-2024)
4.3 Americas Basal insulin/GLP-1RA Combination Preparations Sales Growth
4.4 APAC Basal insulin/GLP-1RA Combination Preparations Sales Growth
4.5 Europe Basal insulin/GLP-1RA Combination Preparations Sales Growth
4.6 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations Sales Growth
5 Americas
5.1 Americas Basal insulin/GLP-1RA Combination Preparations Sales by Country
5.1.1 Americas Basal insulin/GLP-1RA Combination Preparations Sales by Country (2019-2024)
5.1.2 Americas Basal insulin/GLP-1RA Combination Preparations Revenue by Country (2019-2024)
5.2 Americas Basal insulin/GLP-1RA Combination Preparations Sales by Type (2019-2024)
5.3 Americas Basal insulin/GLP-1RA Combination Preparations Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Basal insulin/GLP-1RA Combination Preparations Sales by Region
6.1.1 APAC Basal insulin/GLP-1RA Combination Preparations Sales by Region (2019-2024)
6.1.2 APAC Basal insulin/GLP-1RA Combination Preparations Revenue by Region (2019-2024)
6.2 APAC Basal insulin/GLP-1RA Combination Preparations Sales by Type (2019-2024)
6.3 APAC Basal insulin/GLP-1RA Combination Preparations Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Basal insulin/GLP-1RA Combination Preparations by Country
7.1.1 Europe Basal insulin/GLP-1RA Combination Preparations Sales by Country (2019-2024)
7.1.2 Europe Basal insulin/GLP-1RA Combination Preparations Revenue by Country (2019-2024)
7.2 Europe Basal insulin/GLP-1RA Combination Preparations Sales by Type (2019-2024)
7.3 Europe Basal insulin/GLP-1RA Combination Preparations Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations by Country
8.1.1 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations Sales by Country (2019-2024)
8.1.2 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations Revenue by Country (2019-2024)
8.2 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations Sales by Type (2019-2024)
8.3 Middle East & Africa Basal insulin/GLP-1RA Combination Preparations Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Basal insulin/GLP-1RA Combination Preparations
10.3 Manufacturing Process Analysis of Basal insulin/GLP-1RA Combination Preparations
10.4 Industry Chain Structure of Basal insulin/GLP-1RA Combination Preparations
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Basal insulin/GLP-1RA Combination Preparations Distributors
11.3 Basal insulin/GLP-1RA Combination Preparations Customer
12 World Forecast Review for Basal insulin/GLP-1RA Combination Preparations by Geographic Region
12.1 Global Basal insulin/GLP-1RA Combination Preparations Market Size Forecast by Region
12.1.1 Global Basal insulin/GLP-1RA Combination Preparations Forecast by Region (2025-2030)
12.1.2 Global Basal insulin/GLP-1RA Combination Preparations Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Basal insulin/GLP-1RA Combination Preparations Forecast by Type (2025-2030)
12.7 Global Basal insulin/GLP-1RA Combination Preparations Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Basal insulin/GLP-1RA Combination Preparations Product Portfolios and Specifications
13.1.3 Novo Nordisk Basal insulin/GLP-1RA Combination Preparations Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Basal insulin/GLP-1RA Combination Preparations Product Portfolios and Specifications
13.2.3 Sanofi Basal insulin/GLP-1RA Combination Preparations Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂